Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Medical device maker files option plan for CEO
August 15th, 2005
Iridex Corporation (IRIX) announced that in accordance with NASDAQ Marketplace Rule 4350(i)(1)(A)(iv), as amended, it has granted a non-qualified stock option to Barry G. Caldwell, the company's new CEO, as an inducement material to Caldwell entering into employment with Iridex. The option is exercisable for 234,104 shares of common stock at an exercise price of $6.07 per share. In addition, Caldwell was granted an Incentive Stock Option exercisable for 65,896 shares of common stock at an exercise price of $6.07 per share under its stockholder approved 1998 Stock Plan. These two option grants were approved by a majority of the independent members of...
Source: Pharma Business Week (2005-08-15)
|
